Skip to main content

Medical Treatments

Volume 499: debated on Wednesday 11 November 2009

To ask the Secretary of State for Health what representations his Department has received on the operation of the National Institute for Health and Clinical Excellence's supplementary advice on appraising treatments which may extend life, at the end of life, since 17 December 2008; and if he will make a statement. (297311)

Between 17 December 2008 and 29 October 2009, the Department has responded to five questions from hon. Members and noble Lords relating to the operation of the National Institute for Health and Clinical Excellence (NICE) end-of-life flexibilities.

Over the same period, the Department has received 495 pieces of correspondence relating to NICE, some of which will relate to the operation of the end-of-life flexibilities. Information on specific correspondence on the flexibilities could be provided only at disproportionate cost.

To ask the Secretary of State for Health to what medicines which (a) have been appraised and (b) are under appraisal by the National Institute for Health and Clinical Excellence's supplementary advice on appraising treatments which may extend life, at the end of life, adopted on 17 December 2008, has been applied; what estimate he has made of the total annual eligible patient population for each indication for each such medicine; what the outcomes were of each completed appraisal; and if he will make a statement. (297314)

The information requested is in the following table.

Appraisal status

Appraisal title

Population (approx)1

End of life criteria fulfilled for all or some of potentially eligible patient population

Recommendation

Published

Sunitinib for the first line treatment of advanced and/or metastatic renal cell carcinoma

4,000

Yes

Partial recommendation

Published

Lenalidomide for the treatment of multiple myeloma

2,100

Yes

Partial recommendation

Published

Bevacizumab for the first-line treatment of advanced and/or metastatic renal cell carcinoma

4,000

Applicability considered by the appraisal committee but did not meet end of life criteria

Not Recommended

Sorafenib for the first and second-line treatment of advanced and/or metastatic renal cell carcinoma

4,000

Yes

Not recommended

Sunitinib for the second-line treatment of advanced and/or metastatic renal cell carcinoma

4,000

Applicability considered by the appraisal committee but did not meet end of life criteria

Not recommended

Temsirolimus for the first-line treatment of advanced and/or metastatic renal cell carcinoma

4,000

Yes

Not recommended

Published

Sunitinib for the treatment of gastrointestinal stromal tumours

150

Yes

Partial recommendation

Ongoing

Lapatinib for the treatment of breast cancer

2,000

Applicability considered by the appraisal committee but did not meet end of life criteria

Final guidance not yet issued

Ongoing

Sorafenib for the treatment of hepatocellular carcinoma

Less than 1,000

Yes

Final guidance not yet issued

Ongoing

Trabectadin for soft tissue sarcoma

500-600

Yes

Final guidance not yet issued

Ongoing

Azacitidine for myelodysplastic syndromes

700

Applicability considered by the appraisal committee but did not meet end of life criteria

Final guidance not yet issued

1 Approximate number of people annually with the condition. This will not necessarily represent the number of patients eligible for treatment with the drug.

Source:

National Institute for Health and Clinical Excellence